The use of naturally occurring alkaloids as therapeutic agents for AD treatment has drawn extensive attention, and the U.S. Food and Drug Administration has recently approved two alkaloids, i.e., galantamine and rivastigmine, which act as cholinesterase inhibitors, for the treatment of AD [4, 5]. Here, BCHE is linked to Alzheimer disease.